Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 19, 2026

Bitcoin To $10M? Major Crypto VC Founder Says 'It's Not That Crazy'

View original at finance.yahoo.com
Bitcoin To $10M? Major Crypto VC Founder Says 'It's Not That Crazy' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin could reach between $5 million and $10 million

    80% confidence

  • Bitcoin is superior store of value to gold based on fungibility, ease of transfer, divisibility, liquidity and resistance to government seizure

    80% confidence

  • Ethereum is earlier in adoption curve than Bitcoin, comparable to Bitcoin in 2019, with many institutions yet to understand it

    80% confidence

  • Bitcoin has a five- to 10-times-larger addressable market than gold based on accessibility and fixed supply

    80% confidence

  • Ethereum could benefit as Bitcoin diversifier with ability to earn yield

    80% confidence

  • Uber analogy: criticism during Series A was taxi industry worth $10 billion, how could Uber be worth more, but Uber now worth $100 billion

    80% confidence

  • Solana is a computational layer with huge upside, architecture suitable for developers to build social and financial applications

    80% confidence

  • $5 million to $10 million Bitcoin price justified by TAM expansion from putting software on phones in front of billions of people, causing market size to grow 5-10x

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com